Testicular Feminization Syndrome A S Townsend MRCOG (for George Pinker FRCOG) (St Mary's Hospital, London)
A woman of 19 came with a history of primary amenorrhcea. Examination revealed a tall young woman of normal female appearance: the breasts were well developed; minimal pubic and no axillary hair was present; the clitoris was hypertrophied and the vagina ended blindly, measuring 1'5 in. in length. On rectal examination, no uterus could be defined.
Chromosome studies showed the patient to be chromatin negative and to have a sex chromosome complement of XY. In view of these findings a diagnosis of the testicular feminization syndrome was made.
The gonads in these patients are believed to secrete androgens and cestrogens and the androgen level is reflected in a raised 17-ketosteroid fraction. In approximately 8-5 % of cases reviewed by Morris (1953) malignant change occurred in the gonads.
The urinary 17-ketosteroid and 17-ketogenic steroid output was found to be raised. Further investigation excluded an adrenal tumour and hyperplasia as being responsible for the high output. The plasma testosterone level was 1 96 pg/100 ml compared with the normal male range of 0-32-1-07 ,ug/100 ml. A review of the literature has failed to reveal a level as high as this.
In view of the high testosterone level, the question arises: have the gonads in this patient undergone malignant change? Further studies are being undertaken and in due course laparotomy will probably be undertaken.
Postscript: The testosterone analyses after administration of dexamethasone and gonadotrophin (HCG) were 1 8 ,g/100 ml and 2-4 ,ug/100 ml, respectively. There is no significant suppression after dexamethasone and a modest increase after HCG which is compatible with a testicular source. Laparotomy is being arranged. A patient aged 27 had a five-year history of systemic lupus erythematosus with progressive renal involvement. She had been treated continuously with steroids and, so that the dosage might be reduced, was given azathioprine, an immuno-suppressive and cytotoxic drug. Whilst on this regime she became pregnant but it was not recognized until the twelfth week because of previous menstrual irregularity. At this time it was found that the azathioprine had suppressed her marrow, her haemoglobin falling to 2-8 g (20%). The azathioprine was stopped, she was transfused and the marrow picture returned to normal. Despite blood urea levels of up to 250 mg/100 ml, severe proteinuria and a blood pressure of 170/110 mmHg the pregnancy continued. A superimposed pre-eclamptic toxemia developed at the 32nd week and an elective CQsarean section was performed at the 35th week. The baby weighed 1,729 g, hemopoiesis was unaffected and no abnormalities were detected clinically.
The increased incidence of abortion in pregnancies complicated by systemic lupus erythematosus may be due to some abnormal immune response to the pregnancy. This patient had two previous abortions and it may be that this pregnancy continued because of the azathioprine rather than in spite of it.
